StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck dificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%) (%)

Form 8-K Table 3a / 3b Product Sales

QuarterlyAnnual
Latest, Q2 2026
-87.0%
Period ended Jun 30, 2026
Change on a year earlier
-91.0 pts
4.0% in Q2 2025
History
15 quarters
Since Q1 2022
Sources
15
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-87.0%-91.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025-76.0%-72.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025-64.0%-84.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20254.0%-12.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 20256.0%-4.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024-4.0%-36.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202420.0%+23.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202416.0%+8.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202410.0%–Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202332.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-3.0%-40.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 20238.0%-92.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q3 2022Sep 30, 202237.0%–Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022100.0%–Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202299.0%–Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Cite this data

StockData. (2026). Merck Dificid (fidaxomicin — C. difficile infection) — U.S. reported growth YoY (%) (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_dificid_us_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.